TearClear Stock

TearClear is a pharmaceutical company that specializes in providing a disruptive eye health technology.

Sign up today and learn more about TearClear Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About TearClear Stock

TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.

Investors

Bluestem Capital

TearClear

Funding History

May 2017$4.5M
April 2019$5.0M
January 2020$2.8M
August 2020$22.0M
April 2022$5.9M
July 2023$11.8M

Management

Board of Director

Rick A. Heinick

Chief Scientific Officer and Co-Founder

Anuj Chauhan

Chief Executive Officer

Robert Dempsey

Co-Founder

Ken Banta

Founder

Rick A. Heinick

Board Member

Stuart Raetzman

Board Director

Bob Bailey

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo